Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Rhea-AI Summary
Aligos Therapeutics (Nasdaq: ALGS) received a $25M upfront payment from an exclusive license deal with Amoytop for pevifoscorvir sodium in Greater China for chronic hepatitis B.
Aligos is eligible for up to $420M in milestones plus tiered royalties, and the drug gained Breakthrough Therapy Designation in China with priority NDA review.
Positive
- $25M upfront payment from Greater China license for pevifoscorvir sodium
- Eligibility for up to $420M in clinical, regulatory, and sales milestones
- Tiered high single-digit royalties on net sales in licensed territories
- Breakthrough Therapy Designation in China enabling priority NDA review
- Aligos retains development and commercialization rights in US, Europe, Japan, South Korea, and other markets
- Planned China clinical entry of ASO candidate ALG-170675 in Q3 2026
Negative
- None.
Market reaction after pevifoscorvir Greater China partnership: ALGS +4.10% in the Jul 7 session
In the Jul 7 session, ALGS gained 4.10%, reflecting a moderate positive market reaction. Argus tracked a peak move of +46.5% during that session. Argus tracked a trough of -5.0% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 34.8x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | clinical data update | Positive | -2.4% | Positive liver disease data presented at EASL Congress 2026. |
| May 13 | conference abstracts | Positive | +3.1% | Ten abstracts on liver and viral disease pipeline accepted for EASL. |
| May 07 | earnings report | Positive | +6.8% | Q1 2026 results plus pipeline and partnership progress, including China deal. |
| Apr 30 | earnings scheduling | Neutral | +1.7% | Announcement of date to report Q1 2026 financial results. |
| Apr 24 | equity compensation | Neutral | +4.4% | Inducement stock option grants to new employees under 2024 plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Aligos headlines have more often coincided with positive next-day moves, though one prior positive data update was followed by a decline.
Key Terms
breakthrough therapy designation regulatory
center for drug evaluation regulatory
new drug application regulatory
antisense oligonucleotide medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Breakthrough Therapy Designation granted for pevifoscorvir sodium in China
SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of
Under the terms of the agreement, Aligos is also eligible to receive up to
“We are pleased to provide this update on the collaboration with Amoytop,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “The joint steering committee has been formed, Breakthrough Therapy Designation has been granted for pevifoscorvir sodium in China, and we look forward to the continued progression of this program. In addition, we are continuing to build on our relationship with Amoytop’s planned entrance of our antisense oligonucleotide (ASO) ALG-170675 into the clinic in China in the third quarter of 2026. These two drug candidates together demonstrate the promise of next-generation therapies that have the potential to meaningfully change clinical outcomes for patients with chronic HBV infection.”
Breakthrough Therapy Designation is granted to new drugs that treat serious diseases with preliminary evidence of efficacy. Under this designation, pevifoscorvir sodium is eligible for priority review of a New Drug Application (NDA) in China.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials; statements about whether pevifoscorvir sodium development will continue to progress successfully in China or any jurisdiction, whether ALG-170675 will enter clinical trials in the third quarter of 2026, and whether pevifoscorvir sodium and ALG-170675 will change clinical outcomes for patients. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, reliance on collaborators, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com
